Onward Medical: 70 ARC-EX Systems Delivered in Q1, Generating €2M in Revenue
Onward Medical released its Q1 2026 results, highlighted by the delivery of 70 ARC-EX systems and the availability of this therapy in over 100 clinics across the US and Europe. The neurotechnology company also achieved several clinical milestones, including the first recruitment and successful implant in the Empower BP pivotal study. The quarterly revenue reached €2.0M, while the company raised over €40M in April to extend its funding visibility until Q1 2028.
In the first quarter of 2026, Onward Medical delivered 70 ARC-EX systems for both clinical and home use. The company reports that this external spinal cord stimulation platform was available in over 100 clinics in the US and Europe by the end of the quarter. The first home deliveries were also made, notably to individuals within the Veterans Affairs community in the US.
ARC-EX Generates €1.3M in Revenue in the First Quarter
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
ARC-EX is touted by Onward Medical as the first FDA-approved technology in the US to enhance hand strength and sensation following a spinal cord injury. Revenue from ARC-EX sales reached €1.3M in the first quarter, out of a total revenue of €2.0M. While this revenue base remains limited, it supports the commercial launch of the platform.
Clinical Milestones for ARC-IM and ARC-BCI
The quarter was also marked by the first recruitment and successful implant in the global pivotal Empower BP study, conducted at Craig Hospital in Denver. This study aims to assess the safety and efficacy of the implantable ARC-IM system in managing blood pressure instability in individuals with spinal cord injuries. It is set to involve around 20 centers for neurorehabilitation and neurosurgery in the US, Canada, France, Germany, Spain, and the UK. To date, 12 US sites have been activated and are recruiting participants.
Launch of ARC-EX continues to be a resounding success...
Risks mentioned
Retard dans les approbations réglementaires pouvant affecter les délais.
Concurrence accrue dans le secteur de la neurotechnologie.
Opportunities identified
Lancement du système ARC-EX avec succès aux États-Unis.
Récupération de la demande soutenue pour la technologie de stimulation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
